Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2021-03-29 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
西部证券股份有限公司关于圣湘生物科技股份有限公司2020年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities company (西部证券股份有限公司) acting as a sponsor for 圣湘生物科技股份有限公司 regarding the 2020 annual usage and management of funds raised from the company's initial public offering (IPO) on the STAR Market (科创板). It includes detailed financial figures on the amount raised, usage, balance, investment projects, and compliance with regulatory requirements. The document references specific regulatory guidelines related to the management and use of raised funds, and includes an auditor's verification report. The content is focused on the annual report of the use and management of IPO proceeds, which is a specialized financial and regulatory report but not a full annual report (10-K) or an earnings release. It is a standalone audit and verification report on the use of raised funds, consistent with the definition of an Audit Report / Information (AR). The document length (8911 characters) and detailed financial data support it being a substantive report rather than a brief announcement or certification. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2020
2021-03-29 Chinese
圣湘生物科技股份有限公司关于2020年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from 圣湘生物科技股份有限公司 regarding the management and actual use of funds raised in 2020. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and includes detailed financial figures about the amount raised, usage, balances, and cash management of the raised funds. The document is titled as a "专项报告" (special report) on the annual storage and actual use of raised funds, which aligns with disclosures related to capital raising and fund usage. This type of document is typically classified as a Capital/Financing Update (CAP) because it focuses on fundraising activities, the management of those funds, and compliance with regulatory requirements on the use of raised capital. The document length is sufficient and contains substantive financial data and analysis about the fundraising and fund usage, not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2021-03-29 Chinese
圣湘生物科技股份有限公司关于监事辞职及提名监事候选人的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company supervisor and the nomination of a new supervisor candidate. It includes details about the resignation, the legal implications, and the candidate's background. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to any report publication. The content is about changes in the company's supervisory board, which falls under management or board information. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused on personnel changes, confirming this classification.
2021-03-29 Chinese
中审众环会计师事务所（特殊普通合伙）关于圣湘生物科技股份有限公司2020年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' (Audit Report) and is issued by a certified public accounting firm. It contains detailed audit opinions, basis for audit opinions, key audit matters, management and governance responsibilities, and extensive financial statements including balance sheets and profit statements for the fiscal year ending December 31, 2020. The content is consistent with a standalone audit report rather than a full annual report or other filing types. The document length is substantial (15,000 characters), and it contains actual financial data and audit details, not just an announcement or certification. Therefore, the document fits the category of an Audit Report / Information (AR).
2021-03-29 Chinese
圣湘生物科技股份有限公司内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2020 年度内部控制评价报告' which translates to '2020 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2020. The content includes detailed descriptions of internal control scope, evaluation criteria, defect classifications, and conclusions about the effectiveness of internal controls. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. The document length is 3962 characters, which is relatively short but contains substantive content about internal control evaluation, not just an announcement or certification. This fits the definition of an Audit Report / Information (AR) as it is a standalone report on internal control evaluation and related audit opinions, distinct from a full Annual Report (10-K). FY 2020
2021-03-29 Chinese
圣湘生物科技股份有限公司关于2020年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2020 annual profit distribution plan of the company 圣湘生物科技股份有限公司. It details the cash dividend per share, total dividends, reasons for the dividend payout ratio being below 30%, and the intended use of retained earnings. It also mentions the approval process by the board, independent directors, and supervisory board, and states that the plan will be submitted to the 2020 annual general meeting for approval. The document is focused on dividend distribution details and shareholder information related to dividends, not a full annual report or earnings release. Therefore, it fits the category of Notice of Dividend Amount (DIV). The document length is under 5,000 characters and contains substantive dividend information, not just a brief announcement or a report publication notice.
2021-03-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.